Cargando…

Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial

OBJECTIVE: The effectiveness and security of radiofrequency ablation (RFA) in combination with toripalimab (anti‐PD‐1) for the treatment of recurrent hepatocellular carcinoma (HCC) was studied in this article. METHODS: Total of 40 patients were enrolled in the study between September 2019 and Novemb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Zhenyu, Wang, Junxiao, Tu, Bo, Liu, Yane, Yang, Yuqing, Hou, Li, Yang, Xiang, Liu, Xiaoyan, Xie, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652346/ https://www.ncbi.nlm.nih.gov/pubmed/37814921 http://dx.doi.org/10.1002/cam4.6602

Ejemplares similares

Radiofrequency ablation versus hepatic resection for recurrent hepatocellular carcinoma: an updated meta-analysis
por: Yang, Daopeng, et al.
Publicado: (2020)

Laparoscopic repair of diaphragmatic hernia after radiofrequency ablation for hepatocellular carcinoma: Case report
por: Ushijima, Hokuto, et al.
Publicado: (2021)

Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma
por: Kang, Tae Wook, et al.
Publicado: (2017)

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

Effectiveness of radiofrequency ablation versus transarterial chemoembolization for recurrent hepatocellular carcinoma: A meta-analysis
por: Gou, Haoxian, et al.
Publicado: (2022)

Recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: Analysis of the pattern and risk factors
por: Chen, Rui, et al.
Publicado: (2023)

Feeding artery ablation before radiofrequency ablation for hepatocellular carcinoma may reduce critical recurrence
por: Shimizu, Ryo, et al.
Publicado: (2021)

The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma
por: Xu, Zhentian, et al.
Publicado: (2019)

Laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for subphrenic hepatocellular carcinoma
por: Kwak, Min Hwan, et al.
Publicado: (2022)

Long-term outcomes of combined radiofrequency ablation and multipronged ethanol ablation for the treatment of unfavorable hepatocellular carcinoma
por: Liu, Ming, et al.
Publicado: (2023)

Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report
por: Wu, Ying, et al.
Publicado: (2023)

Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
por: Zhou, Qunfang, et al.
Publicado: (2022)

Percutaneous radiofrequency ablation of adrenal metastases from hepatocellular carcinoma: a single-center experience
por: Huang, Jingzhi, et al.
Publicado: (2019)

Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma
por: Zhang, Yan, et al.
Publicado: (2020)

Surgical treatment of bronchobiliary fistula due to radiofrequency ablation for recurrent hepatocellular carcinoma
por: Kim, Dong Hun, et al.
Publicado: (2013)

Meta-Analysis of Repeat Hepatectomy versus Radiofrequency Ablation for Recurrence of Hepatocellular Carcinoma
por: Machairas, Nikolaos, et al.
Publicado: (2022)

Sarcopenia as a Predictive Factor for Recurrence of Hepatocellular Carcinoma Following Radiofrequency Ablation
por: Jaruvongvanich, Varin, et al.
Publicado: (2023)

Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Xu, Yu-Jie, et al.
Publicado: (2021)

Radiofrequency Thermal Ablation of Hepatocellular Carcinomas
por: Lim, Hyo Keun
Publicado: (2000)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma
por: Yuan, Wei, et al.
Publicado: (2018)

Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
por: Zhou, Qunfang, et al.
Publicado: (2022)

Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study
por: Chen, Yongbiao, et al.
Publicado: (2023)

Radiofrequency ablation induces tumor cell dissemination in a mouse model of hepatocellular carcinoma
por: Zhuang, Bowen, et al.
Publicado: (2023)

Noninvasive Fibrosis Marker Can Predict Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation
por: Chung, Hyun Ah, et al.
Publicado: (2016)

Radiofrequency Ablation Versus Reresection in Treating Recurrent Hepatocellular Carcinoma: A Meta-Analysis
por: Cai, Hao, et al.
Publicado: (2014)

Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation
por: Lu, Liang‐He, et al.
Publicado: (2020)

Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation
por: Ma, Hui, et al.
Publicado: (2021)

Predictive value of TRPV2 expression from peripheral blood mononuclear cells on the early recurrence of atrial fibrillation after radiofrequency catheter ablation
por: Ling, Xuebin, et al.
Publicado: (2022)

Improved treatment of early small hepatocellular carcinoma using sorafenib in combination with radiofrequency ablation
por: Gong, Quanyou, et al.
Publicado: (2017)

Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
por: Bu, Yuqing, et al.
Publicado: (2023)

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab
por: Zhou, Huanyu, et al.
Publicado: (2022)

Combined Transarterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Infeasible for Ultrasound-Guided Percutaneous Radiofrequency Ablation: A Comparative Study with General Ultrasound-Guided Radiofrequency Ablation Outcomes
por: Cha, Dong Ik, et al.
Publicado: (2023)

Risk Group Stratification for Recurrence-Free Survival and Early Tumor Recurrence after Radiofrequency Ablation for Hepatocellular Carcinoma
por: Cha, Dong Ik, et al.
Publicado: (2023)

Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma
por: Zhou, Yanming, et al.
Publicado: (2010)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

The Efficacy of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma in a Cohort of 487 Patients
por: Xie, Hui, et al.
Publicado: (2014)

Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
por: Hua, Yijun, et al.
Publicado: (2021)

Use of radiofrequency ablation in the treatment of hepatocellular carcinoma: Experience of ablation protocols
por: MASAYOSHI, TAKAHASHI, et al.
Publicado: (2012)

Frequency, Risk Factors and Survival Associated with an Intrasubsegmental Recurrence after Radiofrequency Ablation for Hepatocellular Carcinoma
por: Tateishi, Ryosuke, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lkaaisv15l64bo9djnkqg8fgej